Search

Your search keyword '"Allegrini, G"' showing total 300 results
Start Over Author "Allegrini, G"
300 results on '"Allegrini, G"'

51. Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest

Author

Falcone, A., Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Barbara, C., Crino, L., Benedetti, G., Evangelista, W., Fanchini, L., Cortesi, Enrico, Picone, V., Vitello, S., Chiara, S., Granetto, C., Porcile, G., Fioretto, L., Orlandini, C., Andreuccetti, M., Masi, G., and Ovest Gruppo Oncologico Nord

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Organoplatinum Compounds, Colorectal cancer, Leucovorin, Neutropenia, Irinotecan, Gastroenterology, Recurrence, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Neoplasm Metastasis, Aged, FOLFOXIRI, business.industry, Middle Aged, medicine.disease, Survival Analysis, Surgery, Oxaliplatin, Oncology, Fluorouracil, Quality of Life, FOLFIRI, Camptothecin, Female, Colorectal Neoplasms, business, Febrile neutropenia, medicine.drug
Abstract

Purpose The Gruppo Oncologico Nord Ovest (GONO) conducted a phase III study comparing fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI [irinotecan 165 mg/m2 day 1, oxaliplatin 85 mg/m2 day 1, leucovorin 200 mg/m2 day 1, fluorouracil 3,200 mg/m2 48-hour continuous infusion starting on day 1, every 2 weeks]) with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI). Methods Selection criteria included unresectable metastatic colorectal cancer, age 18 to 75 years, and no prior chemotherapy for advanced disease. The primary end point was response rate (RR). Results A total of 244 patients were randomly assigned. An increase of grade 2 to 3 peripheral neurotoxicity (0% v 19%; P < .001), and grade 3 to 4 neutropenia (28% v 50%; P < .001) were observed in the FOLFOXIRI arm. The incidence of febrile neutropenia (3% v 5%) and grade 3 to 4 diarrhea (12% v 20%) were not significantly different. Responses, as assessed by investigators, were, for FOLFIRI and FOLFOXIRI, respectively, complete, 6% and 8%; and partial, 35% and 58%, (RR, 41% v 66%; P = .0002). RR confirmed by an external panel was 34% versus 60% (P < .0001). The R0 secondary resection rate of metastases was greater in the FOLFOXIRI arm (6% v 15%; P = .033, among all 244 patients; and 12% v 36%; P = .017 among patients with liver metastases only). Progression-free survival (PFS) and overall survival (OS) were both significantly improved in the FOLFOXIRI arm (median PFS, 6.9 v 9.8 months; hazard ratio [HR], 0.63; P = .0006; median OS, 16.7 v 22.6 months; HR, 0.70; P = .032). Conclusion The FOLFOXIRI regimen improves RR, PFS, and OS compared with FOLFIRI, with an increased, but manageable, toxicity in patients with metastatic colorectal cancer with favorable prognostic characteristics. Further studies of FOLFOXIRI in combination with targeted agents and in the neoadjuvant setting are warranted.

Published
2007
Full Text
View/download PDF

52. Screening for colorectal cancer in Italy: 2011-2012 survey

Author

Zorzi, Manuel, Da Re, Filippo, Mantellini, Paola, Naldoni, Carlo, De Bianchi, Priscilla Sassoli, Senore, Carlo, Turrin, Anna, Visioli, Carmen Beatriz, Zappa, Marco, Crotta, S., Senore, C., Polizzi, S., Sartori, M., Alibrandi, M. P., Germinetti, F., Bestagini, P., Orione, L., Miroglio, T., Faragli, G., Cereda, D., Coppola, L., Zerbi, L., Gramegna, M., Tessandri, L., Imbrogno, P., Rocca, G., Pesenti, B., Schivardi, M., Crisetig, M., Grassi, E., Speziani, F., Gola, G., Gotti, S., Dal Soldà, M., Boldori, L., Moretti, G., Ilardo, A., Ieni, A, Belloni, A., Rossetti, E., Marazza, G., Anghinoni, E., Silvestri, A., Tidone, E., Frammartino, B., Leonardo, N., Deandrea, S., Ceresa, P., Beghi, G., Lucchini, R., Acerbi, L., Lo Buono, F., Cavalieri D'Oro, L., Magenes, G., Camana, L., Cioccarelli, A. M., Fanetti, A. C., Cecconami, L., Bardelli, R., Violini, M., Sambo, F., Domenighini, S., Pieracci, G., Pertile, R., Piffer, S., Fedato, C., Franzo, A., Fabro, J., Gobbato, M., Zanier, L., Bonelli, L., Orlando, M., Vaccari, D., Franxo, A., Scotto, M., Valle, I., Ferrari Bravo, M., Sticchi, C., Maddalo, F., Pensa, F., Naldoni, C., Sassoli De Bianchi, P., Landi, P., Borciani, E., Fornari, F., Gatti, G., Zurlini, C., Zatelli, M., Maradini, F., Paterlini, L., Campari, C., Sassatelli, R., Corradini, R., Goldoni, C., Pasquini, A., Manfredi, M., Baldazzi, P., Nannini, R., Caprara, L., Carpanelli, M. C., Zoli, G., Matarese, V., Triossi, O., Serafini, M., Vitali, B., Falcini, F., Colamartini, A., Giuliani, O., Vattiato, R., Palazzi, M., Imolesi, C., Pazzi, P., Canuti, D., Casale, C., Giovanardi, M., Monticelli, G., Nicolai, C., Vivani, P., Giorgi, D., Finucci, G., Rapanà, M., Epifani, C., Abdelghani, L., Allegrini, G., Maffei, C., Turillazzi, R., Mirri, F., Ceccatelli, P., Rosati, R., Piacentini, P., Visioli, C. B., Falini, P., Amico, P., Ciabattoni, C., Giaimo, M., Prandini, S., Vinti, G., Di Marco, A., Malaspina, M., Corvetti, R., Di Furia, L., Barca, A., Baiocchi, D., Quadrino, F., Di Giacomo, M., Lattanzio, F. M., Minna, M., Di Credico, A., Pizzuti, R., Sigillito, A., Montesi, M. P., Landro, T., Giorno, A., Santino, M., Magrì, G., Ferrara, G., and Masala, R.

Subjects
Flexible sigmoidoscopy, National survey, Faecal immunochemical test, Italy, Colorectal cancer, Screening, Epidemiology, Public Health, Environmental and Occupational Health, Environmental and Occupational Health, Public Health
Published
2015

53. La familia del niño con trastorno del espectro autista: de la detección a la aceptación

Author

Goñi-Sánchez, A. (Adriana) de and Orduna-Allegrini, G. (Gabriela)

Subjects
Trastorno del Espectro Autista, impacto, detección, diagnóstico, orientaciones, recursos, Aceptación, Niño, Apoyos a la familia, Padres, Familia, Colaboración profesionales-familia
Abstract

Este trabajo tiene por finalidad dar a conocer las características principales del Trastorno del Espectro Autista para posteriormente describir la influencia del mismo en el ámbito familiar. Se tiene en cuenta a la familia como fuente de seguridad y estabilidad para el niño durante su desarrollo evolutivo y se lleva a cabo una investigación sobre cómo la presencia de una persona con esta alteración influye en los componentes dentro de esta institución social. La llegada de un niño con TEA al hogar puede producir inseguridad, temor y desesperanza. Sin embargo, conforme los progenitores van conociendo el trastorno que presentan sus hijos y recibiendo apoyo, llegan a un grado de suficiente calma emocional que les permite aceptar la situación en la que se encuentran. Así, los capítulos que componen el presente documento están estructurados como un camino que los padres van a ir siguiendo hasta comprender qué les sucede a sus hijos y cómo afrontar esta realidad.

Published
2015

54. Hacia la integración social de las personas con deficiencia auditiva: La labor del ciudadano como agente rehabilitador e inclusivo

Author

Raquel and Orduna-Allegrini, G. (Gabriela)

Subjects
Deficiencia auditiva, Sordera, Inclusión
Abstract

En este trabajo se ofrece una perspectiva global de la sordera en el mundo, de sus causas, tipos y consecuencias. Esto desemboca en una llamativa comparación de la respuesta médica y educativa ofrecida en países desarrollados y en vías de desarrollo para prevenir y paliar esta deficiencia. A su vez, de acuerdo a las consecuencias y causas expuestas, se coloca al ciudadano como principal vehículo de cambio para la integración social del sordo y la minimización de las consecuencias que la hipoacusia tiene sobre el mismo. Todo ello a través de la utilización de una terminología adecuada, una formación básica a través de las asociaciones y la aplicación de una serie de adaptaciones comunicativas.

Published
2015

55. Hacia la integración social de las personas con deficiencia auditiva: La labor del ciudadano como agente rehabilitador e inclusivo

Author

Cobos-Guerrero, R. (Raquel) and Orduna-Allegrini, G. (Gabriela)

Subjects
Deficiencia auditiva, Sordera, Inclusión
Abstract

En este trabajo se ofrece una perspectiva global de la sordera en el mundo, de sus causas, tipos y consecuencias. Esto desemboca en una llamativa comparación de la respuesta médica y educativa ofrecida en países desarrollados y en vías de desarrollo para prevenir y paliar esta deficiencia. A su vez, de acuerdo a las consecuencias y causas expuestas, se coloca al ciudadano como principal vehículo de cambio para la integración social del sordo y la minimización de las consecuencias que la hipoacusia tiene sobre el mismo. Todo ello a través de la utilización de una terminología adecuada, una formación básica a través de las asociaciones y la aplicación de una serie de adaptaciones comunicativas.

Published
2015

56. Second-line erlotinib or intermittent erlotinib plus docetaxel in male ex-smokers with squamous NSCLC: The TALISMAN randomized trial

Author

Gridelli, C, Chella, A, Valmadre, G, Allegrini, G, Brighenti, M, Bidoli, P, Rossi, A, Maione, P, Migliorino, M, Ricciardi, S, De Marinis, F, Migliorino, MR, Gridelli, C, Chella, A, Valmadre, G, Allegrini, G, Brighenti, M, Bidoli, P, Rossi, A, Maione, P, Migliorino, M, Ricciardi, S, De Marinis, F, and Migliorino, MR

Abstract

Background/Aim: The TArceva and docetaxeL In former-Smokers MAle patients with recurrent non-small cell lung cancer (TALISMAN) phase II, open-label randomized trial evaluates the combination of erlotinib with docetaxel in the second-line therapy of ex-smoker males with advanced squamous non-small cell lung cancer (NSCLC). Patients and Methods: Patients received erlotinib 150 mg/day (arm A; n=36) or docetaxel 75 mg/m2 on day 1 of each 3-week cycle and erlotinib 150 mg/day on days 2-16 of each cycle (arm B; n=38). The primary end-point was progression-free rate (PFR) at 6 months. Results: The study was prematurely interrupted due to slow enrolment. Three (8.3%) patients in arm A and 3 (8.1%) in arm B remained progression-free at 6 months. Median progressionfree survival (PFS) was 2.3 months in arm A and 2.8 months in arm B. Median overall survival (OS) was 5.6 and 8.9 months, respectively. Overall, 77.8% of patients in arm A and 89.2% in arm B experienced treatment-related adverse events (AEs). Conclusion: Results do not support further investigation of the combination of erlotinib and docetaxel in this setting, Background/Aim: The TArceva and docetaxeL In former-Smokers MAle patients with recurrent non-small cell lung cancer (TALISMAN) phase II, open-label randomized trial evaluates the combination of erlotinib with docetaxel in the second-line therapy of ex-smoker males with advanced squamous non-small cell lung cancer (NSCLC). Patients and Methods: Patients received erlotinib 150 mg/day (arm A; n=36) or docetaxel 75 mg/m2 on day 1 of each 3-week cycle and erlotinib 150 mg/day on days 2-16 of each cycle (arm B; n=38). The primary end-point was progression-free rate (PFR) at 6 months. Results: The study was prematurely interrupted due to slow enrolment. Three (8.3%) patients in arm A and 3 (8.1%) in arm B remained progression-free at 6 months. Median progressionfree survival (PFS) was 2.3 months in arm A and 2.8 months in arm B. Median overall survival (OS) was 5.6 and 8.9 months, respectively. Overall, 77.8% of patients in arm A and 89.2% in arm B experienced treatment-related adverse events (AEs). Conclusion: Results do not support further investigation of the combination of erlotinib and docetaxel in this setting.

Published
2016

57. 214P - Pre-specified interim analysis of the SAFE trial (NCT2236806): A 4-arm randomized, double-blind, controlled study evaluating the efficacy and safety of cardiotoxicity prevention in non-metastatic breast cancer patients treated with anthracyclines with or without trastuzumab

Author

Livi, L., Barletta, G., Martella, F., Desideri, I., Scotti, V., Becherini, C., Saieva, C., Terziani, F., Bacci, C., Airoldi, M., Allegrini, G., Amoroso, D., Venditti, F., Tarquini, R., Orzalesi, L., Sanchez, L., Bernini, M., Nori, J., Fioretto, L., and Meattini, I.

Published
2019
Full Text
View/download PDF

58. Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies

Author

Rossini, D., primary, Casagrande, M., additional, Moretto, R., additional, Loupakis, F., additional, Cremolini, C., additional, Masi, G., additional, Borelli, B., additional, Lonardi, S., additional, Zagonel, V., additional, Aprile, G., additional, Ricci, V., additional, Grande, R., additional, Tomasello, G., additional, Ronzoni, M., additional, Allegrini, G., additional, Tonini, G., additional, Mancini, M.L., additional, Zaniboni, A., additional, Chiara, S., additional, Carlomagno, C., additional, and Falcone, A., additional

Published
2016
Full Text
View/download PDF

60. P-237 - Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial

Author

Dell'Aquila, E., Pantano, F., Rossini, D., Stellato, M., Lonardi, S., Masi, G., Schirripa, M., Marmorino, F., Antoniotti, C., Murgioni, S., Tomasello, G., Ronzoni, M., Racca, P., Vincenzi, B., Allegrini, G., Urbano, F., Buonadonna, A., Banzi, M., Tonini, G., Cremolini, C., Falcone, A., and Santini, D.

Published
2018
Full Text
View/download PDF

63. Clinical presentation in BRCA1/2 mutation carriers: a single-institution experience

Author

Ferrarini, I., Fontana, A., Aretini, P., Bona, E., Stasi, I., Bartolini, I., Laurà, F., Salvadori, B., Landuci, E., Michelotti, A., Allegrini, G., Lucchesi, S., Arrighi, G., Congregati, C., Bonci, F., Rossetti, E., Fustaino, L., Roncella, M., Caligo M, A., Bevilacqua, G., Simi, P., and Alfredo Falcone

Published
2012

64. A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO)

Author

Salvatore, L., GIANLUCA MASI, Loupakis, F., CHIARA CREMOLINI, Schirripa, M., Fornaro, L., Antoniotti, C., Vivaldi, C., Granetto, C., Fea, E., Antonuzzo, L., Giommoni, E., Boni, C., Banzi, M., Chiara, S., Sonaglio, C., Allegrini, G., Marcucci, L., Valsuani, C., Greco, F., Safina, V., Boni, L., and Alfredo Falcone

Published
2012

66. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses

Author

Falcone, A., primary, Cremolini, C., additional, Antoniotti, C., additional, Lonardi, S., additional, Ronzoni, M., additional, Zaniboni, A., additional, Tonini, G., additional, Salvatore, L., additional, Masi, G., additional, Mezi, S., additional, Tomasello, G., additional, Carlomagno, C., additional, Allegrini, G., additional, Chiara, S., additional, D'Amico, M., additional, Granetto, C., additional, Lupi, C., additional, Sensi, E., additional, Fontanini, G., additional, Boni, L., additional, and Loupakis, F., additional

Published
2015
Full Text
View/download PDF

73. E7 - A retrospective analysis of patients (pts) with non-small-cell lung cancer (NSCLC) with uncommon or complex epidermal growth factor receptor (EGFR) mutations treated with tyrosine kinase inhibitors (EGFR-TKIs): clinical features and outcome

Author

Stasi, I., Farnesi, A., Vasile, E., Petrini, I., Luccchesi, M., Lupi, C., Sensi, E., Giannini, R., Fornaro, L., Caparello, C., Pasquini, G., Puppo, G., Finale, C., Barletta, M., Chella, A., Allegrini, G., Falcone, A., and Fontanini, G.

Published
2017
Full Text
View/download PDF

74. Phase III Trial of infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) compared with infusional Fluorouracil,Leucovorin, and Irinotecan (FOLFIRI) as first-line treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest(G.O.N.O.)

Author

Alfredo Falcone, Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Barbara, C., Crin, L., Benedetti, G., Evangelista, W., Fanchini, L., Cortesi, E., Picone, V., Vitello, S., Chiara, S., Granetto, C., Porcile, G., Fioretto, L., Orlandini, C., Andreuccetti, M., and GIANLUCA MASI

Published
2007

80. First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.)

Author

Bursi, S., GIANLUCA MASI, Loupakis, F., Antonuzzo, A., Tognarini, L., Sonaglio, C., Chiara, S., Pfanner, E., Brunetti, I., Iacopo Petrini, Baldi, G. G., Barletta, M. T., Fornaro, L., Allegrini, G., Donati, S., Andreuccetti, M., Ricci, S., and Alfredo Falcone

Published
2007

85. Low-dose metronomic cyclophosphamide plus celecoxib and dexamethasone in advanced hormone refractory prostate cancer (HRPC): a phase II clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination

Author

Fontana, A., Guido Bocci, Galli, L., Fontana, E., Antonuzzo, A., Galli, C., Loupakis, F., Allegrini, G., Di Marsico, R., Landi, L., Lo Dico, M., Mazzoni, E., Safina, V., Barletta, M., Andreuccetti, M., Barsanti, G., Fioravanti, A., Orlandi, P., Del Tacca, M., and Alfredo Falcone

Published
2006

86. Bevacizumab

Author

Allegrini, G., Marcucci, L., Barbara, C., Fontana, A., and Falcone, Alfredo

Published
2005

87. Raccomandazioni cliniche per i principali tumori solidi

Author

Allegrini, G., Amoroso, D., Angioli, D., Arcangeli, Annarosa, Bechi, Paolo, Biti, G., Calvaruso, V., Celona, G., Di Giorgi, U., Di Lieto, M., Fabbrucci, P., Fiorentini, G., Franceschini, F., Fucini, Claudio, Galardi, A., Gasperoni, S., Genuardi, M., Goletti, O., Grazzini, G., Janni, A., Lazzi, S., Manetti, A., Mantellini, P., Masi, A., Mazza, E., Medi, F., Messerini, L., Mignogna, M., Mini, E., Moretti, R., Morettini, A., Mosca, F., Naspetti, R., Paci, E. £., Pinto, E., Ponticelli, P., Pirtoli, L., Piliti, M., Ribecco, A. S., Sainato, A., Sarnelli, R., Seccia, M., Tagliagambe, A., Tanzini, G., Tonelli, F., Valanzano, R., Valeri, A., and Venturini, G.

Subjects
raccomandazioni cliniche, tumori solidi
Published
2005

89. Folfoxiri Plus Bevacizumab (Bv) or Plus Anti-Egfr Antibodies in Ras and Braf Wild-Type (Wt) Metastatic Colorectal Cancer (Mcrc) Patients (Pts): Analysis of Tumor Response

Author

Salvatore, L., primary, Cremolini, C., additional, Loupakis, F., additional, Masi, G., additional, Schirripa, M., additional, Marmorino, F., additional, Bergamo, F., additional, Zagonel, V., additional, Aprile, G., additional, Allegrini, G., additional, Tonini, G., additional, Zaniboni, A., additional, Amoroso, D., additional, Boni, C., additional, Gamucci, T., additional, Pinto, C., additional, Corsi, D.C., additional, D'Amico, M., additional, Bracarda, S., additional, and Falcone, A., additional

Published
2014
Full Text
View/download PDF

91. 5 FU + Irinotecan

Author

Falcone, Alfredo, Masi, G., Cupini, S., Cerri, E., and Allegrini, G.

Published
2003

95. Educación para el desarrollo humano, educación como ayuda al crecimiento

Author

Naval, C. (Concepción) and Orduna-Allegrini, G. (Gabriela)

Subjects
Ayuda al desarrollo, Eduación, Desarrollo humano
Abstract

El fenómeno social de la pobreza, es una de las mayores preocupaciones de las políticas de desarrollo a escala mundial, y es también uno de los más dificiles de solucionar. A pesar de los logros conseguidos hasta el momento, no se ha podido romper su presencia cíclica en todos los países del planeta. Con la mirada esperanzada puesta en el futuro, se propone en este trabajo titulado “Educación para el desarrollo humano, educación como ayuda al crecimiento”, una tesis sencilla: se trata de procurar prepapar el desarrollo, a través de la educación, en la infancia. Lo sugerente de la propuesta es que, aquí, se entiende la educación como ayuda al crecimiento y que el desarrollo para ser eficaz debe ser puesto en marcha en el ámbito más cercano a las personas: el local o comunitario. Así, y como forma de luchar contra la pobreza, se propone una educación que, desde la infancia, prepare a los individuos para actuar de forma libre, comprometida y responsable en la mejora de las condiciones de vida que le rodean. Cuánto más crezca cada miembro de la comunidad como persona, más activamente podrá luchar contra la pobreza y a favor de su propio desarrollo y el de sus convecinos.

Published
2001

98. D14 - Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies

Author

Rossini, D., Casagrande, M., Moretto, R., Loupakis, F., Cremolini, C., Masi, G., Borelli, B., Lonardi, S., Zagonel, V., Aprile, G., Ricci, V., Grande, R., Tomasello, G., Ronzoni, M., Allegrini, G., Tonini, G., Mancini, M.L., Zaniboni, A., Chiara, S., Carlomagno, C., and Falcone, A.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results